Comparative Pharmacology
Head-to-head clinical analysis: LYBALVI versus SEZABY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYBALVI versus SEZABY.
LYBALVI vs SEZABY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYBALVI is a combination of olanzapine and samidorphan. Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C, dopamine D1-D4, histamine H1, and alpha1-adrenergic receptors. Samidorphan is an opioid receptor antagonist with high affinity for mu-opioid receptors, hypothesized to reduce olanzapine-associated weight gain by blocking opioid receptors in the central nervous system.
Positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
Olanzapine 10 mg / samidorphan 10 mg orally once daily.
58 mg subcutaneously once monthly (every 30 days).
None Documented
None Documented
Terminal half-life ~20-30 hours; supports once-daily dosing.
The terminal elimination half-life of Sezaby is approximately 24 hours in healthy adults. This supports once-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40%; Biliary: minor.
Sezaby undergoes extensive hepatic metabolism, with approximately 75% of the dose excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites. Renal clearance accounts for less than 5% of total clearance.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic